Recurrence After Treatment of Micropapillary Thyroid Cancer

Ross, Douglas S.; Litofsky, Danielle R.; Ain, Kenneth B.; Bigos, Thomas; Brierley, James D.; Cooper, David S.; Haugen, Bryan R.; Jonklaas, Jacqueline; Ladenson, Paul W.; Magner, James A.; Robbins, Jacob; Skarulis, Monica C.; Steward, David L.; Maxon, Harry R.; Sherman, Steven I.

doi:10.1089/thy.2008.0407

Cited by 180 publications

(123 citation statements)

References 18 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Retrospectively analyzing 889 patients with pT1-2 well-differentiated thyroid cancer, Nixon and colleagues 30 found that patients undergoing thyroid lobectomy had no difference in local or regional recurrence. In contrast, Ross and colleagues 31 showed that in 611 patients, micropapillary multifocal disease, in particular, demonstrated reduced risk of recurrence after total thyroidectomy (6%) compared with patients who underwent less than complete resection (18%). Given that the majority of our fvPTC cohort demonstrated multifocal disease, patients who undergo lobectomy alone might benefit from ongoing monitoring of the contralateral side, with the understanding that the likelihood of a clinically significant cancer developing is low.…”

Section: Discussionmentioning

confidence: 92%

Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer

Sullivan

Graham

Alexander

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer

Sullivan

Graham

Alexander

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

“…Adicionalmente, y aunque el número de casos es pequeño, encontramos igual cantidad de pacientes con recidiva tratados y no tratados con radioyodo; algo similar a lo encontrado por Ross et al 22 , quien demostró que la terapia con I-131 no redujo las recurrencias en pacientes con patología multifocal o con linfonodos afectados; esto debiera ser estudiado por ensayos clínicos controlados y aleatorizados, a fin de establecer el verdadero valor de la terapia con radioyodo en este tipo de pacientes.…”

Section: Discussionunclassified

Análisis de factores de agresividad de microcarcinoma papilar de tiroides

et al. 2013

Rev Chil Cir

View full text Add to dashboard Cite

Features influencing aggressiveness of papillary thyroid microcarcinomaBackground: The risk factors determining the aggressiveness of papillary thyroid microcarcinoma (PTMC) are not well known. Aim: To determine if tumor size, along with other features of the tumor, influences its prognosis. Patients and Methods: We analyzed the medical records of 147 patients (age range 16-92 years, 93% women) at the Clinical Hospital of University of Chile who underwent thyroid surgery and in whom at least one focus of PTMC was found. We determined the association between different clinical characteristics and the presence of capsular invasion, lymph nodal extension or recurrence. Results: A tumor size over 5 mm, a follicular subtype and being aged more than 45 years, were significantly associated with the presence of capsular invasion. The latter two variables were protective. In the multivariate analysis, only a tumor size over 5 mm was significantly associated with thyroid capsule involvement. Conclusions: A tumor size over 5 mm is associated with capsular invasion in PTMC.

show abstract

“…The data collection and analytical methods of the NTCTCS have been described elsewhere (8,9,(14)(15)(16)(17)(18)(19)(20). Briefly, 11 North American centers contributed patient data, with registration beginning in January 1987 (this data analysis captures patients registered through to 2011).…”

Section: Registry Protocol and Data Collectionmentioning

confidence: 99%

Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis

McLeod

Jonklaas

Brierley

et al. 2015

Thyroid

Self Cite

View full text Add to dashboard Cite

Background: Thyroid cancer is unique for having age as a staging variable. Recently, the commonly used age cut-point of 45 years has been questioned. Objective: This study assessed alternate staging systems on the outcome of overall survival, and compared these with current National Thyroid Cancer Treatment Cooperative Study (NTCTCS) staging systems for papillary and follicular thyroid cancer. Methods: A total of 4721 patients with differentiated thyroid cancer were assessed. Five potential alternate staging systems were generated at age cut-points in five-year increments from 35 to 70 years, and tested for model discrimination (Harrell's C-statistic) and calibration (R 2 ). The best five models for papillary and follicular cancer were further tested with bootstrap resampling and significance testing for discrimination. Results: The best five alternate papillary cancer systems had age cut-points of 45-50 years, with the highest scoring model using 50 years. No significant difference in C-statistic was found between the best alternate and current NTCTCS systems ( p = 0.200). The best five alternate follicular cancer systems had age cut-points of 50-55 years, with the highest scoring model using 50 years. All five best alternate staging systems performed better compared with the current system ( p = 0.003-0.035). There was no significant difference in discrimination between the best alternate system (cut-point age 50 years) and the best system of cut-point age 45 years ( p = 0.197). Conclusions:No alternate papillary cancer systems assessed were significantly better than the current system. New alternate staging systems for follicular cancer appear to be better than the current NTCTCS system, although they require external validation.

show abstract

Recurrence After Treatment of Micropapillary Thyroid Cancer

Cited by 180 publications

References 18 publications

Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer

Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer

Análisis de factores de agresividad de microcarcinoma papilar de tiroides

Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis

Contact Info

Product

Resources

About